REG - Hikma Pharmaceutical - Additional Listing

Hikma PharmaceuticalsAnnouncement

10/01/2023 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230110:nRSJ2909Ma&default-theme=true

RNS Number : 2909M  Hikma Pharmaceuticals Plc  10 January 2023

Block Listing of Shares

Hikma Pharmaceuticals PLC

 

LONDON, 10 January 2023 - The Board of Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (LEI: 549300BNS685UXH4JI75) (NASDAQ: HIK), announces that it has
made a block listing application to the Financial Conduct Authority and the
London Stock Exchange plc for a total of 1,200,000 ordinary shares of 10p each
in the capital of the Company to be admitted to the Official List of the UK
Listing Authority.  It is expected that admission will be granted on 12
January 2023.

 

The shares, when issued, will be issued fully paid and rank pari passu in all
respects with the existing issued ordinary shares of the Company.  The shares
will be issued pursuant to the vesting of shares under the Hikma
Pharmaceuticals PLC 2018 Management Incentive Plan and 2014 Executive
Incentive Plan (the "Plans"). Participants in the Plans have or will become
entitled to these shares following the vesting of the shares.

 

 

- ENDS -

 

Enquiries

 

 Hikma Pharmaceuticals PLC
 Helen Middlemist           +44 (0) 2073992760

 Deputy Company Secretary

 

About Hikma

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,700 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit www.hikma.com (http://www.hikma.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSGPUGCGUPWGAU